Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback